Broomfield, CO-based Biodesix has closed on a $20 million Series D financing led by existing investors. The new capital will support ongoing commercialization activities for the company's first product, VeriStrat, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer.
The funding also will support the company's ongoing collaborations with several biotechnology and pharmaceutical firms seeking diagnostics to identify the most appropriate patients for their targeted oncology therapies, according to Biodesix CEO David Brunel.
Biodesix was founded in 2005 and has been a leader in personalizing medicine by introducing VeriStrat, which helps physicians determine if a patient should receive treatment with erlotinib, an epidermal growth factor inhibitor.
- see the Biodesix release